The content discusses how a simple blood test measuring four biomarkers in patients with type 2 diabetes (T2D) and kidney disease can predict the risk of heart and kidney disease progression. The study analyzed data from the CREDENCE trial, showing that patients treated with canagliflozin had lower biomarker levels after one year. High baseline concentrations of these biomarkers predicted future risks for renal and heart outcomes. The study suggests that combining these biomarkers into a panel can significantly predict the likelihood of experiencing the composite endpoint. The results are exploratory, and further research is needed to refine the predictive value of the panel. The study highlights the importance of biomarker-based testing in enhancing risk prediction for individuals with T2D.
翻譯成其他語言
從原文內容
www.medscape.com
從以下內容提煉的關鍵洞見
by Liam Davenpo... 於 www.medscape.com 08-21-2023
https://www.medscape.com/viewarticle/995670深入探究